March 2022: Abacwaningi base-University of Texas MD Anderson Cancer Centre bathole ukuthi i-axi-cel, i-autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), iyindlela yokwelapha yomugqa wokuqala ephephile nesebenzayo yeziguli ezine-B-cell enkulu esengozini enkulu. i-lymphoma (LBCL), iqembu elidinga kakhulu izindlela zokwelapha ezintsha nezisebenzayo.
Lokhu okutholakele kwethulwe ku-American Society of Hematology's virtual 2020 Annual Meeting.
Ngokwesiko, cishe uhhafu weziguli ezine-LBCL esengozini enkulu, iqeqebana lesifo lapho iziguli zine-lymphoma ephindwe kabili noma kathathu noma izici ezengeziwe zengozi yomtholampilo ezihlonzwe yi-International Prognostic Index (IPI), azizange zizuze isifo sesikhathi eside. ukukhululwa ngezindlela zokwelashwa ezijwayelekile ezifana ne-chemoimmunotherapy.
Lesi sivivinyo simele isinyathelo esiya ekwenziweni Ukwelashwa kwamaseli e-CAR T indlela yokwelapha yomugqa wokuqala yeziguli ezine-B-cell lymphoma enolaka,” kusho uSattva S. Neelapu, MD, uprofesa we Lymphoma kanye ne-Myeloma. “Okwamanje, iziguli ezisanda kutholakala ukuthi zine-B-cell lymphoma zithola ukwelashwa ngamakhemikhali cishe izinyanga eziyisithupha. Ukwelashwa kwamaseli e-CAR T, uma iphumelele, ingase ikwenze ukufakwa kanye kuphela ngokwelashwa okuqedwe enyangeni eyodwa.
Ngokusekelwe ocwaningweni olubalulekile i-ZUMA-1, i-Axi-cel njengamanje inelayisensi yokwelapha abantu abane-LBCL ebuyele emuva noma ephikayo asebevele benemigqa emibili noma ngaphezulu yokwelapha okuhleliwe. Uhlolo lwe-ZUMA-12 luyiSigaba 2 esinelebula evulekile, ingalo eyodwa, uhlolo olugxile ezintweni eziningi olwakhelwa kulokho okutholwe ocwaningweni lwe-ZUMA-1 ukuze kuhlolwe ukusetshenziswa kwe-axi-cel njengokwelashwa komugqa wokuqala ezigulini ezine-LBCL esengozini enkulu. .
Ngokocwaningo lwesikhashana lwe-ZUMA-12, amaphesenti angama-85 eziguli ezelashwa nge-axi-cel abe nempendulo ephelele, kanti ama-74% abe nempendulo ephelele. Ngemuva kokulandelela okumaphakathi kwezinyanga ezingu-9.3, i-70% yeziguli eziqashiwe zibonise impendulo eqhubekayo ekunqanyulweni kwedatha.
Ukunciphisa inani lamaseli amhlophe egazi, i-encephalopathy, i-anemia, kanye i-cytokine release syndrome kwakuyimiphumela emibi kakhulu exhunywe nokwelashwa kwe-axi-cel. Ngesikhathi idatha ihlaziywa, zonke izehlakalo ezimbi zase zixazululiwe.
Ngaphezu kwalokho, uma kuqhathaniswa nalapho imikhiqizo ye-immunotherapy yenziwa ezigulini esezivele zithole imigqa eminingana ye-chemotherapy, izinga eliphakeme lamaseli e-CAR T akhona egazini, kanye nokunwetshwa kwamaseli e-CAR T amaphakathi, ayephezulu kulolu cwaningo. umugqa wokuqala Ukwelashwa kwamaseli e-CAR T.
"Lokhu kufaneleka kwe-T cell kungaxhunyaniswa nempumelelo enkulu yokwelapha, okuholela emiphumeleni engcono yesiguli," wanezela uNeelapu.
Kulandela imiphumela emihle yesikhashana ye-ZUMA-12, abacwaningi bahlela ukuqhubeka nokulandelela iziguli ukuze baqinisekise ukuthi ukusabela kwazo emithini kuhlala isikhathi eside.
"Ukuhlolwa komtholampilo okungahleliwe kuzodingeka ukuze kubonise ngokuqinisekile ukuthi ukwelashwa kwe-CAR T cell kuphakeme kunezinga elikhona lokunakekelwa nge-chemoimmunotherapy kulezi ziguli ezisengozini enkulu uma izimpendulo ziphikelela ngemva kokulandelwa isikhathi eside," kusho uNeelapu. Kuphinde kubuze umbuzo wokuthi ngabe i-CAR T cell Ukwelashwa kufanele kuhlolwe ezigulini ezisengozini emaphakathi ezine-B-cell enkulu i-lymphoma.
